https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5045 Sat 24 Mar 2018 07:45:38 AEDT ]]> Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26254 Sat 24 Mar 2018 07:40:18 AEDT ]]> All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25283 Sat 24 Mar 2018 07:38:13 AEDT ]]>